BCTX
BriaCell Therapeutics Corp.NASDAQHealthcare$4.10+5.37%ClosedMarket Cap: $7.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.40
P/S
0.00
EV/EBITDA
0.59
DCF Value
$4.22
FCF Yield
-417.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-221.7%
ROA
-129.4%
ROIC
-123.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $0.00 | -Infinity% | $-7.7M | $-7.2M | $-2.58 | — |
| Q1 2026 | $0.00 | -Infinity% | $-11.5M | $-11.4M | $-4.35 | — |
| Q4 2025 | $0.00 | -Infinity% | $-11.7M | $-11.1M | $-5.87 | — |
| FY 2025 | $0.00 | -Infinity% | $-37.7M | $-36.5M | $-86.25 | — |
| Q3 2025 | $0.00 | -Infinity% | $-9.0M | $-8.7M | $-23.33 | — |
| Q2 2025 | $0.00 | -Infinity% | $-10.3M | $-9.1M | $-33.57 | — |
| Q1 2025 | $0.00 | -Infinity% | $-7.0M | $-7.9M | $-44.55 | — |
| Q4 2024 | $0.00 | -Infinity% | $-7.9M | $-1.7M | $-13.91 | — |
| FY 2024 | $0.00 | -Infinity% | $-45.5M | $-6.5M | $-59.69 | — |
| Q3 2024 | $0.00 | -Infinity% | $-12.4M | $2.3M | $21.68 | — |
| Q2 2024 | $0.00 | -Infinity% | $-13.3M | $-15.3M | $-143.32 | — |
| Q1 2024 | $0.00 | -Infinity% | $-11.4M | $8.1M | $-100.18 | — |